Last $6.01 USD
Change Today -0.20 / -3.22%
Volume 39.1K
CERU On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

cerulean pharma inc (CERU) Snapshot

Open
$6.18
Previous Close
$6.21
Day High
$6.18
Day Low
$5.81
52 Week High
04/14/14 - $8.06
52 Week Low
08/5/14 - $3.35
Market Cap
121.0M
Average Volume 10 Days
25.5K
EPS TTM
--
Shares Outstanding
20.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CERULEAN PHARMA INC (CERU)

Related News

No related news articles were found.

cerulean pharma inc (CERU) Related Businessweek News

No Related Businessweek News Found

cerulean pharma inc (CERU) Details

Cerulean Pharma Inc., a clinical-stage company, develops nanopharmaceutical product candidates in the areas of oncology and other diseases in the United States. The company’s lead product candidate is CRLX101, a tumor targeted nanopharmaceutical, which is in Phase II clinical trials for the treatment of relapsed renal cell carcinoma and relapsed ovarian cancer; and in Phase Ib clinical trials for the treatment of neoadjuvant rectal cancer, as well as in Phase II clinical trials for other indications, such as gastric cancer and small cell lung cancer. It is also developing CRLX301, a nanopharmaceutical with docetaxel that is in preclinical stages for the treatment of solid tumors. The company was formerly known as Tempo Pharmaceuticals, Inc. and changed its name to Cerulean Pharma Inc. in October 2008. Cerulean Pharma Inc. was incorporated in 2005 and is based in Cambridge, Massachusetts.

22 Employees
Last Reported Date: 04/14/14
Founded in 2005

cerulean pharma inc (CERU) Top Compensated Officers

Principal Executive Officer and Chief Operati...
Total Annual Compensation: $368.8K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $378.8K
Consultant
Total Annual Compensation: $528.0K
Compensation as of Fiscal Year 2013.

cerulean pharma inc (CERU) Key Developments

Cerulean Pharma Inc. Announces First Patient Dosed with CRLX301 in Phase 1/2a Trial in Advanced Solid Tumors

Cerulean Pharma Inc. announced that the first patient has been dosed with CRLX301 in Cerulean’s Phase 1/2a trial in patients with advanced solid tumor malignancies. CRLX301 is a nanoparticle-drug conjugate, or NDC, with a docetaxel payload, and it is the second clinical candidate from Cerulean’s Dynamic Tumor Targeting Platform. This is the first clinical trial of CRLX301. The Phase 1/2a trial is commencing in Australia and is expected to expand to the U.S. The Phase 1 portion is a single-arm, open-label, dose-escalation study of CRLX301 in up to 36 patients with advanced solid tumor malignancies that is designed to identify the maximum tolerated dose and establish the recommended Phase 2 dose of CRLX301 when administered by intravenous infusion once every three weeks. The Phase 2a portion will be an expansion cohort that will enroll an additional 24 patients. The primary endpoints are pharmacokinetics, safety and tolerability of CRLX301. Preliminary evidence of efficacy also will be evaluated.

Cerulean Pharma Inc. Announces Completion of Enrollment of Phase 1B/2 Study of CRLX101 in Combination with Avastin® in Relapsed Renal Cell Carcinoma

Cerulean Pharma Inc. announced completion of enrollment of 22 patients in a Phase 1b/2 clinical proof of principle trial of its lead nanoparticle-drug conjugate, CRLX101, in combination with Avastin® in relapsed renal cell carcinoma (RCC). This study is an investigator-sponsored trial (IST) being conducted by the University of Pennsylvania and Thomas Jefferson University Hospital with support from Cerulean. The Principal Investigator is Dr. Stephen Keefe of the University of Pennsylvania Abramson Cancer Center. Data previously presented from the first 11 patients from this study showed a 27% response rate (three RECIST responses) in a setting where standard of care historically provides only a 2-4% response rate. A 7.6 months median progression-free (PFS) survival was observed, which is double the roughly 3.5 months PFS achieved by standard-of-care in this setting. Based on these data, Cerulean launched a company-sponsored randomized Phase 2 trial of CRLX101 in combination with Avastin in 3rd and 4th line RCC in August 2014, which is currently ongoing.

Cerulean Pharma Inc. Announces Management Changes

Cerulean Pharma Inc. announced that Paul A. Friedman, M.D., who has served as a member of the Board since January 2014, was appointed as Executive Chairman, effective upon the Separation Date. As Executive Chairman, Dr. Friedman will, among other duties, oversee the company’s operations, including the clinical and regulatory functions. In connection with Dr. Friedman’s appointment as Executive Chairman and effective upon the Separation Date, (i) Dr. Friedman resigned as a member of the Compensation Committee of the Board and the Nominating and Corporate Governance Committee of the Board, (ii) William T. McKee replaced Dr. Friedman as a member of the Nominating and Corporate Governance Committee and (iii) Alan Crane ceased serving as Chairman of the Board. Mr. Crane will continue to serve as a director of the company. In addition, on October 25, 2014, the company appointed Christopher D. T. Guiffre, J.D. as its Chief Operating Officer, effective upon the Separation Date. Mr. Guiffre, has served as the company’s Senior Vice President and Chief Business Officer since 2012. In connection with Mr. Guiffre’s promotion to Chief Operating Officer and principal executive officer of the company, Karen L. Roberts, the company’s Senior Vice President of Finance and Administration, shall serve as the company’s principal financial officer, effective upon the Separation Date. Ms. Roberts has served as the company’s Senior Vice President of Finance and Administration since 2010. On October 25, 2014, the Board appointed David R. Parkinson, M.D. as a Class II director, effective as of the Separation Date, to fill the vacancy created by the resignation. Dr. Parkinson will serve as a member of the class of directors whose terms expire at the 2016 annual meeting of stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. In connection with his election to the Board, Dr. Parkinson will serve on the Board’s newly created Clinical Advisory Committee, along with existing directors Dr. Susan Kelley and Dr. Friedman. Dr. Friedman will serve as chairman of the Clinical Advisory Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERU:US $6.01 USD -0.20

CERU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CERU.
View Industry Companies
 

Industry Analysis

CERU

Industry Average

Valuation CERU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,453.2x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 735.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERULEAN PHARMA INC, please visit www.ceruleanrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.